Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.75 |
| ▸ | NPC1 | O15118 | 8/20 | 0.75 |
| ▸ | RAB9A | P51151 | 7/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 4/20 | 0.75 |
| ▸ | HTT | P42858 | 4/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | CCR1 | P32246 | 3/20 | 0.58 |
| ▸ | CCR5 | P51681 | 3/20 | 0.58 |
| ▸ | CCR8 | P51685 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055382 | 0.88 | KDM4E (0.58) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1456153 | 0.87 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30211369 | 0.87 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1456985 | 0.87 | KDM4E (1.00) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17055543 | 0.86 | KDM4E (0.55) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17055380 | 0.86 | TP53 (0.55) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4189211 | 0.84 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4174742 | 0.84 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4178522 | 0.84 | KDM4E (0.95) | KDM4ENPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1456375 | 0.82 | KDM4E (0.67) | KDM4ENPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447075-B2 | Pyridazine derivatives as EAAT2 activators | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | KDM4E 1381/4885NPC1 730/4885RAB9A 3311/4885 |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | KDM4E 2333/4885NPC1 4663/4885RAB9A 4745/4885 |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | KDM4E 743/4885NPC1 2665/4885RAB9A 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.